Vorozole: Difference between revisions
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Drugbox | |||
| Verifiedfields = changed | |||
| Watchedfields = changed | |||
| verifiedrevid = 470631940 | |||
| IUPAC_name = 6-[(4-Chlorophenyl)(1,2,4-triazol-1-yl)methyl]-1-methylbenzotriazole | |||
| image = Vorozole.svg | |||
<!--Clinical data--> | |||
| tradename = | |||
| pregnancy_category = | |||
| legal_status = | |||
| routes_of_administration = | |||
<!--Pharmacokinetic data--> | |||
| bioavailability = Very high | |||
| metabolism = Hepatic | |||
| elimination_half-life = 8 hours | |||
| excretion = | |||
<!--Identifiers--> | |||
| CAS_number_Ref = {{cascite|changed|??}} | |||
| | | CAS_number = 118949-22-7 | ||
| CAS_number=118949-22-7 | | ATC_prefix = L02 | ||
| ATC_prefix=L02 | | ATC_suffix = BG05 | ||
| ATC_suffix=BG05 | | PubChem = 6918191 | ||
| | | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | ||
| | | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ||
| | | ChemSpiderID = 5293402 | ||
| C = 16 | H = 13 | Cl = 1 | N = 6 | | UNII_Ref = {{fdacite|correct|FDA}} | ||
| UNII = 1E2S9YXV2A | |||
| KEGG_Ref = {{keggcite|correct|kegg}} | |||
| KEGG = D03786 | |||
| ChEMBL_Ref = {{ebicite|correct|EBI}} | |||
| ChEMBL = 224060 | |||
<!--Chemical data--> | |||
| C=16 | H=13 | Cl=1 | N=6 | |||
| molecular_weight = 324.768 g/mol | | molecular_weight = 324.768 g/mol | ||
| | | smiles = Clc1ccc(cc1)[C@@H](c2ccc3nnn(c3c2)C)n4ncnc4 | ||
| | | InChI = 1/C16H13ClN6/c1-22-15-8-12(4-7-14(15)20-21-22)16(23-10-18-9-19-23)11-2-5-13(17)6-3-11/h2-10,16H,1H3/t16-/m0/s1 | ||
| InChIKey = XLMPPFTZALNBFS-INIZCTEOBI | |||
| | |||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
'''Vorozole''' is an [[aromatase | {{CMG}} | ||
==Overview== | |||
'''Vorozole''' is an [[imidazole]] based [[competitive inhibitor]] of the [[aromatase]] enzyme. It underwent clinical testing for evaluation for use as an [[antineoplastic]] agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent [[megestrol acetate]] and research instead focused on the other third generation [[aromatase inhibitors]] [[anastrozole]], [[letrozole]] and [[exemestane]]. | |||
It is selective.<ref name="pmid9797019">{{cite journal |author=Goss PE |title=Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor |journal=Breast Cancer Res. Treat. |volume=Suppl 1 |issue= |pages=S59–65; discussion S73–7 |series=49 |year=1998 |pmid=9797019 |doi= 10.1023/a:1006052923468 |url=http://www.kluweronline.com/art.pdf?issn=0167-6806&volume=49%20Suppl%201&page=S59}}</ref> | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Aromatase inhibitors]] | [[Category:Aromatase inhibitors]] | ||
[[Category: | [[Category:Organochlorides]] | ||
[[Category:Drug]] | |||
Latest revision as of 15:47, 10 April 2015
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | Very high |
| Metabolism | Hepatic |
| Elimination half-life | 8 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C16H13ClN6 |
| Molar mass | 324.768 g/mol |
| 3D model (JSmol) | |
| |
  (what is this?) (verify) | |
|
WikiDoc Resources for Vorozole |
|
Articles |
|---|
|
Most recent articles on Vorozole |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Vorozole at Clinical Trials.gov Clinical Trials on Vorozole at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Vorozole
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating Vorozole Risk calculators and risk factors for Vorozole
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Vorozole |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Vorozole is an imidazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.
It is selective.[1]
References
- ↑ Goss PE (1998). "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor" (PDF). Breast Cancer Res. Treat. 49. Suppl 1: S59–65, discussion S73–7. doi:10.1023/a:1006052923468. PMID 9797019.
- Pages with script errors
- Articles with changed CASNo identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Aromatase inhibitors
- Organochlorides
- Drug